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It has been shown that a  complement-fixing (CF) antigen can be prepared 
with  a  variant  of  the  Type 2  (Lansing-like)  MEF1  strain  of poliomyelitis 
"titus adapted innewborn mice (1, 2). The antigen reacted with sera obtained 
from several species of immune animals and from persons with poliomyelitis. 
Later Lahelle  (3)  prepared effective Type  2,  CF  antigens  from the  central 
nervous  system  (CNS)  tissue  of  infected newborn  cotton  rats.  Pollard  (4) 
succeeded in preparing a  Type 2,  CF antigen from the CNS tissue of mature 
cotton rats  infected with Lansing  virus  by purifying and  concentrating the 
virus in the ultracentrifuge. Recently it was reported (5) that the same tech- 
nique yielded CF antigens of low potency from the  CNS  tissue of monkeys 
infected  with  Type  1  (Brnnhflde-like)  or  Type  3  (Leon-like)  poliomyelitis 
virus. The present investigation had been concluded when Svedmyr, Enders, 
and Holloway (6) reported the preparation of CF antigens from tissue cultures 
infected with Brnnhilde and Lansing viruses. The monkey sera tested by all 
of these investigators yielded type-specific CF reactions. 
A  considerable number of children, recently convalescent from poliomyeli- 
tis, were found to possess significant serum titers of CF antibody for the Type 
2  antigen despite  the fact that  they had  no Type 2  neutralizing antibodies 
(2). Since, with one possible exception, all the Type 1-immune or convalescent 
monkey sera and one Type 3 (Leon)-immune monkey serum failed to fix com- 
plement  with  this  Type 2  antigen  (2),  it  appeared  possible  that  in  human 
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beings  the  CF  antibody  response  to  infection  with  poliomyelitis  virus  was 
not  necessarily  type-specific. With  the  establishment  of a  practical  CF  test, 
it  became  necessary  to  investigate  the  development  and  significance  of the 
Type 2 poliomyelitis  CF antibody in the monkey and in man. The rapid  de- 
velopment of Type 2, CF antibody in cynomolgus monkeys infected by mouth 
with Type 2 poliomyelitis virus is described separately (7). The present paper 
deals  with  the  occurrence,  development,  persistence,  and  significance  of the 
Type  2,  CF  antibody  in human  beings  with special  reference to the pattern 
observed  after  infection  with  other  types  of poliomyelitis  virus.  Four  main 
groups of individuals were investigated: (a)  Patients who were proved to have 
been infected with Type  1 poliomyelitis virus by recovery and  typing of the 
virus,  and  in  some  instances  also  by  the  development  of homologous neu- 
tralizing  antibody  in  increasing  titer.  Appropriate  neutralization  tests  with 
Lansing virus indicated that this group of patients had either no preceding or 
concurrent infection with Type 2 virus.  (b)  Patients  on whom tests for virus 
were negative, but whose sera showed on neutralization test that they had had 
no previous or current infection with Type 2 virus.  (c) Patients with a  clinical 
diagnosis  of  poliomyelitis  on  whom  no  data  had  been  obtained  regarding 
infection  with  Type  2  or  other  types  of poliomyelitis  virus.  (d)  Individuals 
without history of poliomyelitis, in the same general age group as the patients, 
some bled  during  the  late  summer  or autumn  and  others  during  the  winter 
months.  Tests  on early acute phase and serial  convalescent serum specimens 
of each of 32 patients  provided information  on the  rapidity  of development 
and persistence  of Type 2,  CF antibody in patients  infected with other types 
of poliomyelitis virus. 
Materials and Methods 
Virus.--The MEF1 variant virus adapted to newborn mice (1, 8), in its 75th to 100th 
passage in such mice, was used as a source of antigen. The mean titer of the virus of these 
passages, as determined  by intracerebral  inoculation into 4- to 5-week-old mice, in groups 
of 8 to 10 or 20 per dilution, was 5.6 ±  0.274; the incubation period following intracerebral 
inoculation of 10  -~ dilution of virus into 3- or 4-day-old mice was 2.2 days, and of these in- 
jected mice 90 to 100 per cent were paralyzed within48 hours. Tests with antigens prepared 
from normal brain and from Japanese B and Western equine encephalitis viruses were included 
as controls. 
All the conditions of the tests followed the description already given (2) with exceptions 
as will be noted. 
A,bigens.---Changes in the preparation  of the antigen (2) were: (a) the brains of mice sacri- 
riced at 48 hours after inoculation, or at a time when 90 to 100 per cent exhibited paralysis, 
were the source of antigen.  (b) In the interests  of simplification and expedition, only brain, 
not spinal cord, was used. Control antigens of normal tissue, Japanese B and Western equine 
encephalitis viruses also contained brain but no cord. (c) With increase in the number of serial 
animal passages, the titer of the antigen increased. Instead of a titer of 1: 2 or 1:4, rarely 1:8, 
to passage 70, from passage 78 to 110, titrations  of 7 lots of antigen containing 20 to 150 ml. 
in each show as follows: Passages 78 to 79, 1:8; 80 to 82, 85 to 94, and 97 to 100, 1:16, 95 J.  CASALS~ P.  K.  OLITSKY,  AND  A.  B.  SABIN  37 
to 96, 97, 101 to 106, 1:32. At such high titers, the antigens were comparable to those of the 
encephalitis viruses now in general use for their specific diagnosis (9,  10). With such highly 
active antigens, however, a  "zone" effect was noted, an effect first described by Espana and 
Hammon (11)  for encephalitis viruses and later confirmed in this laboratory and by Lahelle 
for poliomyelitis antigen (3). Accordingly, the MEF1 antigens were diluted to no less than 8 
and no more than 16 units for use in the tests; as a  rule, the desired point was at 1:8, 4-}-, 
and 1:16,  2-3+.  Control antigens were also diluted to contain the same concentration of 
brain tissue. 
Scra from poliomyelitis-convalescent persons, who had been tested with the earlier low 
titered antigens (2), revealed generally a higher titer on retesting with the more recent high 
titered reagent. Consequently, although almost ali sera discussed in this communication were 
originally tested with low titered antigens, they were retested with high titered antigens, and 
the results recorded here for the sera derived  from poliomyelitis patients and normal con- 
trois were obtained with 8 to 16 units of antigen. It should be noted, however, that no signif- 
icant qualitative change in the results was thus obtained, because sera which yielded negative 
or dubious results with low titered antigen did not become positive in the tests with high 
titered antigens. 
Sera.--In accord with the practice in this laboratory, all human sera were heated for 20 
minutes at 60°C. Since the present study is based on comparative results obtained with sera 
from individuals with or without clinicaliy recognized poliomyelitis, special care was taken to 
intersperse test and control specimens. Thus, from 25 to 40 different sera were tested at one 
time for reaction to MEF1 and one or two control antigens, including the usual controls for 
anticomplementary effects of serum and antigen. In  the repeated testing of so many sera 
1:4 was used as the first dilution; this was necessitated, first by the smali amount of serum 
at hand, and second by the fact that fixation with an undiluted serum or 1:2 dihtion of it 
was of dubious meaning (2). The titer was read as the highest dilution of serum added to the 
mixture, which yielded a 2+ or greater reaction; when there was a 4+ in one dilution and 0 
to lq- in the next, the titer was found by interpolation. 
Test.--The procedure, previously described  (2), was not changed. As a  check on the re- 
producibility of the titers, positive control sera were added to each series, often positive human 
sera and always mouse hyperimmune serum. An ample supply of the latter provided enough 
for many repetitions and the titer was invariably the same; the titers obtained in different 
tests can therefore be regarded as comparable. 
Neutralization  Tests.--Qualitative  tests,  and  when  necessary  quantitative  as  well  for 
Type 2 neutralizing antibody, were performed in mice using the Lansing strain of virus. In 
the qualitative tests the mixtures consisted of undiluted serum and 5-fold or 10-fold  dilutions 
of virus, the result being expressed as the neutralization index, which is  the control titer 
divided by the titer of the virus in the serum. A neutralization index of 50 or over was regarded 
as significant. In the quantitative test the mixtures consisted of serial 4-fold dilutions of serum 
and 50 LDs0 of virus, the result being expressed as the 50 per cent final serum dilution end- 
point. The sera of some of the patients listed in Table I were tested in monkeys for antibody 
against the strain of virus recovered from the patient's own alimentary tract, and some of 
these results have already been reported (12). In one of the patients, Kan., listed in Table I, 
the recovered Type  1 virus was of insufficient potency for quantitative neutralization tests 
in  monkeys.  Since the CF  data obtained on  this patient  made it desirable  to  determine 
whether the recovered Type  1 virus was being passively carried or actually caused the dis- 
ease, neutralization tests were carried out in monkeys, using a Type 1 virus recovered from an- 
other patient, Obe., in the same epidemic. Mixtures consisting of serial 4-fold dilutions of serum 
and  100  PD60  of virus were inoculated into groups of 4 rhesus monkeys, and the 50 per cent 
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TABLE  I 
Type 2, CF Antibody in Patients Infected with HeteTotypic S~ralns of Poliomyditis  Virus 
Virus  Type of 
recovery  illness 
Paralytic 
Positive 
(Type 1) 
Non-paralytic 
Paralytic 
Negative 
Non-paralytic 
Patient  Type 2 neutralizing  Time 
antibody  after 
onset 
Ist 
Name  Age  1st serum  3 mos. 
yrs. 
Obe.*  13  0~  0 
Smi. ¶  13  0  0 
Hopp.  I,  5  0  0 
Hopk.*  2  1:12"*  1:11 
Kau.*  11  1:32  0 
Yea.  2  0  0 
Kni.  2  0  0 
Fal.  36  0  0 
Den.¶  5  0  0 
Sic.  15  1:6  1:38 
Col.  12  1:16  1:32 
Pet.  13  1:3  1:17 
Vau.  8  0(0, 0)$:~  1:16 
Bre.  12  0  0 
WoL  2  1:1024][[I  1:724 
Oaf.  12  1:680[[][  1:910 
Let.  5  0  0 
Sny.  5  0  0 
Wor,  7  0  0 
Sea.  7  0  0 
Cah.  3  0  0 
Gra.  16  0  0 
Cur.  3  0  0 
Ack.  18  + 
Bru.  15  -t- 
GiI,  11  q- 
Hal.  12  + 
Hud.  11  I:4]JH  1:4 
Fru.  12  -+.  1:256¶¶ 
Ten.  12  O(O,O)~t  1:128 
Mac.  5  0(0,1:22)***  1:4 
CF titer with MEF1 antigen 
serum  1st  2 
obtained  serum  wks. 
days 
1  O§  1211  8  4 
3  64  32  16  0 
4  6  12  8  6 
2  8  24  24  4 
3  128  128  96  64 
0.3  4  8  4  0 
1  192  128  96  48 
3  16  32  32  32 
0.3  0  0  0  0 
1  96  64  64  32 
1  12  32  32  32 
2  16  128  54  24 
5  16  8  12  48§§ 
5  48  48  32  24 
3  0  128  96  64 
4  12  24  24  16 
1  24  24  12  0 
1  6  12  8  6 
I  32  48  64  64 
1  0  0  0  0 
2  0  0  0  0 
4  0  4  4  0 
4  256  64  64  32 
1  0  0  0  0 
1  0  0  0  0 
2  8  8  6  6 
3  0  0  0  0 
3  4  128  48  16 
4  12  32  24  16 
4  64  64  32  16§§ 
3  6  6  128"**  12 
w4s.  3  mos. 
* These  )atieuts were tested for homotypic neutralizing antibody and  exhibited an increasing titer  during 
convalescence. 
0 ffi neutralization  index of <50 for undiluted  serum. 
§ 0  =  <  1:4;  see text. 
U 12 =  1:12 meaning that there was 4-{-- fixation at 1:8 and 0 or It  at I: 16. 
¶  Smi, and Den. viruses not typed. 
** Serum dilution protecting 50 per cent of mice against 50 LD~ of virus. 
:~ 0(0,0)  =  neutralizing antibody  negative in acute phase and 2-week and 4-week serum specimens. 
§§ The neutralizing antibody  tests suggest that a  Type 2 poliomyelitis virus infection occurred  between 4 
weeks and 3 months after onset of the clinicaily recognized attack of poliomyelitis. 
[]I[ The 2-week and 4-week Lansing antibody titers were about the same as that of the acute phase serum. 
¶¶ The 2-week and 4-week Lansing antibody titers were about the same as in the 3-month serum; acute phase 
specimen contained antibody but was lost before titration. 
*** 0(0,1:22)  =  neutralizing  antibody  negative in acute phase and 2-week specimen but positive in titer 
of 1:22 in 4-week serum, suggesting a  superimposed  Type 2 poliomyelitis virus infection during convalescence 
from first attack; the late rise in CF titer is compatible with this assumption. ~.  CASA.LS~ P.  K.  OLITSKY~  AND  A.  B.  SABIN  39 
RESULTS 
CF  tests were performed on  single  or multiple serum  specimens from 81 
patients  with  a  clinical  diagnosis  of poliomyelitis, and  on  those  from  159 
individuals of similar age groups  without clinically recognized poliomyelitis. 
31  of the poliomyelitis patients were part  of a  group which was thoroughly 
investigated in ways described in a  previous communication (12)  and subse- 
quently also by quantitative neutralization tests with Lansing virus. Since the 
poliomyelitis viruses recovered from this group of patients were also investi- 
gated in the typing program (13), and since 4 serial serum specimens, from the 
acute phase to 3 months after onset, were available in each case, the results 
with these 31  patients are presented separately (group A).  In the remaining 
50 patients  (group B)  there was no such detailed information and the avail- 
able sera were mostly single or two-phase specimens obtained at various in- 
tervals after onset. 
FINDINGS  IN GROUP  A  POLIOMYELITIS PATIENTS.-- 
Thirty-five patients were primarily studied in this group, with low titered antigen~ but the 
results summarized in Table I  include only the 31 patients whose sera were tested with opti- 
mum antigen. The 4 patients thus excluded were all infected with Type 1 poliomyelitis virus, 
as determined by virus recovery and development of homologous neutralizing antibody in 
increasing titer, and they exhibited no evidence of previous or concurrent infection with Type 
2 virus. 2 of these 4 developed no significant Type 2, CF antibody; that of one changed from 
a titer of less than 1:2 in the serum obtained I day after onset to titers of 1:4 at 2  weeks  and 
4 weeks respectively, and was less than 1:2 again at 3 years after onset; another had titers 
of 1:8 and 1:4 respectively at 2 weeks and 4 weeks, and less than 1:2 at 3 years after onset. 
The procedures used in the attempted recovery of virus from these 31  patients have al- 
ready been described (12). 11 of the 13 strains were shown to be of Type 1 (13)  and those of 
patients Smi. and Den. were not typed; however, the failure of these 2 patients to develop 
neutralizing antibody for the Lansing virus shows that the virus responsible for their infection 
also was not Type 2. Only 3 of this group of 13 patients were tested for development of homolo- 
gous antibody; Obe. had a final serum dilution titer of 1:2 in the acute phase specimen and 
1:64 in the 3 month convalescent specimen, when tested against his own virus, and Hopk. 
showed a rise in titer from 1 : 32 in the acute phase serum to 1 : 214-{- in the 3 month specimen, 
against his own virus. Patient Kan.'s sera tested with the Obe. virus, showed a  rise in titer 
from 1:32 during the acute phase to 1:128 at 3 months after onset." 
For a proper interpretation of the significance of the Type 2, CF antibody response in these 
patients it is not enough to establish that the patient experienced infection with Type 1 polio- 
myelitis virus, but it is also necessary to know whether or not he might have had a preceding 
or concurrent infection with a  Type  2  poliomyelitis virus.  This information was  obtained 
by means of neutralization tests with the Lansing virus. When both the acute phase and 3 
month specimens gave negative results in this test the patient was regarded as having had no 
preceding or concurrent infection with a Type 2 virus. When the acute phase serum neutralized 
Lansing virus in the qualitative test and significant CF  titers were obtained, quantitative 
tests for Lansing antibody were performed by the serum dilution method on serial specimens 
to determine whether or not the titer changed in a  manner comparable to that observed in 
tests with the patient's own strain of virus (12). 
The results of these neutralization tests, presented in Table I, show several patterns. There 40  TYPE 2 POLIOMYELITIS COMPLEMENT-FIXING A_N!TIBODY 
are individuals in whom the Lansing neutralizing antibody titers show no significant differ- 
ence between the earliest  acute phase and 3 month convalescent sera, and it can be concluded 
that such patients (e.g., Hopk., Col., Wol., Gaff, and Hud.) had been infected with a Type 2 
virus in the past, not during the period of their illness. Then there is the patient, e.g. Kau., 
who has Lansing neutralizing antibody in a titer of 1:32, 3 days after onset and none 3 months 
after onset; the test, repeated with identical results on two occasions, showed that the Lansing 
antibody dropped to a Liter of 1:2 at 2 weeks and was absent at 4 weeks after onset (14). 
Since this patient's current illness was proved to be due to infection with Type 1 poliomyelitis 
virus, by recovery of the virus and development of an increasing titer of homotypic neutralizing 
antibody within 3 months after onset, it appeared possible that a transitory rise in Type 2 
neutralizing antibody may occur in some patients infected with Type 1 virus. This question 
has been studied more extensively by Sabin (14) who obtained further evidence for the oc- 
currence of this transitory response in heterotypic neutralizing antibody. In patients such as 
Sic. and Pet., in whom the Lansing neutralizing antibody titer is seen to be about 6 times 
higher at 3 months after onset than in the acute phase, one has difficulty in deciding whether 
the Type 2 neutralizing antibody response is due to the heterotypic stimulation by the Type 
1 virus, which was recovered from their alimentary tract, or to a concurrent infection with a 
Type 2 virus. The former  supposition is perhaps favored by the demonstration, not shown 
in Table I, that in both patients the titer was somewhat higher at 4 weeks than at 3 months 
(14). 
The data on patients Van., Ten., and Mac., who had no Lansing neutralizing antibodies 
during the acute phase or 2 weeks after onset, but developed them between the 2nd and 4th 
week (Mac.) or between the 4th and 12th week (Vau. and Ten.), suggest a dual type of infec- 
tion separated by an interval of weeks--the second one, presumably due to infection with the 
Type 2 virus, being clinically inapparent. This assumption gains support from the fact that 
a marked rise in the Type 2, CF titer occurred in Mac. and Vau.  at the same time as the 
Lansing neutralizing antibody changed from negative to positive. In patient Ten.  the CF 
antibody rise was either missed during the 2 month interval or failed to occur because  the 
first infection with a non-Lansing  type of virus called forth a very high titer of Type 2, CF 
antibody. 
It is plain from the data just given that in none of the 31 patients presented 
in Table I  was there evidence that the illness under investigation was caused 
by a  Type 2 poliomyelitis virus, although the majority of them exhibited high 
titers  of Type  2,  CF antibody in  their  acute  phase  sera  or  developed such 
antibody shortly thereafter.  Only 4  of the  31  (Obe.,  Pet.,  Wol.,  and  Hud.) 
exhibited a  4-fold or greater difference in titer between the acute phase and  2 
week  serum  specimens.  Excepting  the  3  patients  (Vau.,  Ten.,  and  Mac), 
whose  Lansing  neutralizing antibody data  suggest  a  superimposed  infection 
with  Type  2  poliomyelitis virus  some  weeks  after  the  current  illness,  there 
was no further increase in CF titer between the 2week and 4  week specimens. 
The  first serum  specimen was  obtained within  24  hours  of onset of the first 
fever or symptoms (headache, nausea, sore throat, etc.) in 39 per cent, within 
3  days in  74 per cent,  and  in all 31  patients within 5  days.  It is apparent, 
therefore, that the failure to demonstrate a  4-fold or greater rise in CF anti- 
body in a  larger proportion of the patients must be due to the fact that  the 
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infection. The arithmetical mean of the titers during the first 5 days was 1:33 
as compared with  1:38 at 2  weeks after onset. The conclusion that  in most 
patients showing no demonstrable increase in titer the CF antibody actually 
developed during  the  current illness is  based  on  two  considerations  (a)  the 
very low incidence of similar titers in the control group, to be described shortly, 
and  (b)  the tendency for the CF antibody to disappear or drop in titer at 3 
months. Thus, in 2 patients (Smi. and Let.) with peak titers of 1:24 and 1:64 
at  1 or 3 days after onset, the titers were 0  (<1:4)  at 3 months. A 4-fold or 
greater drop in titer occurred at 3 months in 9 of 18 patients who exhibited 
titers of 1:16 or greater during the first 4 weeks (patient Vau.  was not con- 
TABLE II 
Type 2, CF Antibody Response during First 2 Weeks in Group A  Patients, with Reference 
to Presence or Absence of Evidence of Previou* or Concurrent Infection with Type 2 
Poliomyelitis Virus 
Evidence of infection with Type 2 
poliomyelitis virus 
None before or during first 2 wks. of 
current illness 
Before  but not during first 2 wks. of 
current illness 
Virus recovery 
+ 
+  and -- 
+ 
+  and  -- 
No. Of 
patients 
9* 
19 
t§ 
7H 
8 
No. with indicated peak CF titer 
<4  4-12  16 or > 
3  5 
3  5 
6  10 
3  1  3 
3  1  4 
Patients Sic., Col., Pet., and Fru. are excluded from this analysis. 
* Patients Obe., Smi., Hopp., Kau., Yea., Kni., Fal., Den., and .Vau. 
:~ Patients Bre., Let., Sny., Wor., Sea., Cab., Gra., Cur., Ten., and Mac. 
§ Patient Hopk. 
][ Patients Wol., Gal., Ack., Bru., GiL, Hal., and Hud. 
sidered  because  of evidence  of a  later  superimposed  infection).  This  rapid 
development of CF  antibody in  maximum  titer  should  be  contrasted  with 
the  somewhat  slower  rise  in  the  titer  of homotypic  neutralizing  antibody 
(12, 15). 
Relationship between Occurrence  of Type 2, CF Antibody and Preceding In- 
fection  with  Type  2  Poliomyelitis  Virus.--The  data summarized in Table II 
are arranged to determine whether or not the Type 2,  CF antibody response 
in individuals without sign of previous or concurrent infection with Type 2 
virus  differs from that  in  individuals  with  evidence of prior infection. The 
data  show no such  difference either with  regard  to  the  number who failed 
to develop CF antibody or those who developed titers of 1:16 or higher. The 
data in Table I, furthermore, show that the occurrence of very high titers of 
CF  antibody very shortly after onset does not  depend on previous or con- Virus recovery 
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current  infection with  Type 2  poliomyelitis virus  (patients  Cur.,  Wor.,  Let., 
Bre.,  Kni., Smi.). 
Incidence of Type 2, CF Antibody in Rdation to  Virus Recovery and Type of 
Clinical Disease.--The  summary presented  in Table  III is based  on titers  of 
1:16 or higher, because  titers  of this magnitude were encountered only infre- 
quently in the control group, and on the response during the first  2 weeks in 
order to permit  inclusion of the patients  with  a  superimposed  infection after 
TABLE III 
Summary of CF Antibody Response during First 2 Weeks in Group A Patients, with Reference 
to Virus Recovery and Type of Disease 
Type of disease 
+ 
"~  and  -- 
No. ( 
mtients 
Paralytic 
Non-paralytic 
Total .................. 
Paralytic 
Non-paralytic 
Total .................. 
Paralytic 
Non-paralytic 
'Total .................. 
5 
8 
13 
3 
15 
18 
9 
3 
6 
9 
6 
12 
18 
8 
23 
31 
Peak CF tlter during first 2 wks. 
16 or >  32 or > 
I Per ce t  No.  Per cent  No. 
3  60  2 
6  I  75  5 
69  7 
42 
100  2 
40  5 
50  7 
75  4 
52  10 
58  14 
40 
62 
54 
67 
33 
39 
50 
43 
45 
that  time.  In the 13  patients,  from whom virus was recovered,  there  was no 
difference  in response  among those  who had  the  paralytic  disease  and  those 
with a  non-paralytic infection;  69 per cent of these  13 patients  had  titers  of 
1:16 or over and 54 per cent, titers of 1:32 or over. This does not include one 
patient  (Obe.)  who exhibited at least a 4-fold increase in titer, which however 
did not exceed  1:12. Among the  18 patients  with negative tests for virus,  all 
3 paralytic patients had titers of 1 : 16 or over, while only 40 per cent of those 
with  a  diagnosis  of non-paralytic poliomyelitis  had  titers  of this  magnitude. 
While  the numbers are  too small for statistical  significance, it is not improb- 
able that some of these patients may have had aseptic meningitis due to some 
agent other than the virus of poliomyelitis. At any rate it is clear that somewhat 
more than 70 per cent of patients,  infected with non-Lansing strains of polio- 
myelitis virus, exhibit either a  significant rise in heterotypic Type 2, CF anti- 
body or titers  of  a  magnitude  only infrequently  encountered  in  controls. 3.  CASALS, P.  K.  OLITSKY 7 AND  A.  B.  SABIN  43 
FINdinGS z~ G~ouP B  POLIOMYELITIS PATIENTS.-- 
The patients  in this  group were not studied  as thoroughly as those  in group A. Only in 4 
were attempts made to isolate the virus from  the alimentary tract; from these 4, Type  1 
virus was recovered. Of the 50 patients in this group, 39 were paralytic; 7, non-paralytic, and 
4 of uncertain type. Their ages ranged from 6 months to 15 years, the greatest number being 
1 to 9 years old. 
CF Antibody: Development and Persistence.--Two serial serum specimens were  obtained 
from 27 patients of whom 22 were paralytic, 3 non-paralytic, and 2 of uncertain clinical type; 
the first, 1 to 7 days after onset and the second, from 13 to 82 days after onset, in 20 patients 
between the 27th and the 35th day. A 4-fold, or greater, rise in titer between the first and 
second specimens, from a  negative finding at 1:4 to positive at 1:12, was observed in only 
TABLE  IV 
CF  Tiers  in  Patients of  Group B 
Titer of serum 
<24* 
4--12 
16-24 
32-48 
64-96 
128  or  > 
No. 
Acute phase  Convalescent 
2 
6 
4 
13 
4 
3 
Per cent 
6.3 
18.7 
12.5 
40.6 
12.5 
9.4 
No.  Per cent 
5  11.4 
11  25.0 
9  20.4 
15  34.1 
3  6.8 
1  2.3 
Total ..........................  32  44 
* Figures represent denominator of dilution. 
one of these patients. In contrast, the second sample in 5 cases, obtained not later than 35 
days after onset, exhibited a 4-fold, or greater, decrease in titer as compared with the first. 
Table IV contains a  summary of the results on 76 serum specimens from the 50 patients; 
all sera collected within 7 days after onset have been placed under the caption "acute phase;" 
"convalescent" means those obtained from li to 135 days  after onset, i.e. 6, after 11 to 17 
days; 27, 25 to 35 days, 10, 44 to 88 days, and 1 after 135 days. These four subgroups show 
no appreciable difference from one another. 
Table IV reveals that 75 per cent of the acute phase sera were positive in a 
dilution  of 1:16  or higher,  and 62.5 per cent in a  dilution  of 1:32  or higher. 
Titers of 1 : 16 or higher were encountered in 63.6 per cent of the convalescent 
sera, and 1:32 or higher in 43.2 per cent. There is no significant difference in 
number or titer of positive reactions among the acute and convalescent phase 
sera.  Finally,  no  comparison  could  be  made  of  the  reaction  in  relation  to 
clinical type of the disease owing to the smaU number of non-paralytic cases. 
It is noteworthy, however, that the 75 per cent incidence of titers of 1:16 or 
higher  in  the  acute phase  sera  of group  B  is  the  same as  that  encountered 
during the first 2 weeks in the  8 paralytic patients in group A  (Table HI). 
CF in Relation to Type 2 Neutralizing  Antibody.--The  results of neutraliza- 44  TYPE 2  POLIOMYELITIS COMPLEM2ENT-FIXING ANTIBODY 
tion tests were  known in 30 patients.  The analysis in Table V  shows no  sig- 
nificant difference in number or titer of positive reactions between those who 
had neutralizing antibody for Type 2 virus  and those who did not. 
General Consideration  of Antibody Reactions in Both Group A  and Group  B. 
--Since the general results of CF tests are similar in the two groups of patients, 
those of the 31 individuals of group A and the 50 of group B  were combined 
for analysis in Table VL The incidence of 23.3 per cent negative CF reactions 
TABLE V 
CF m Pati~ ~GroupB. RdationtoType2 Neu~dizing Antibody 
Neutralization index* 
50 or more 
<50 
No. of patients with indicated CF titer 
No, of patients  ........ 
__  <____~4  4-I__~2  16-48  64 or >  16 or > 
6  [1111  3  I  1  II  4(67percent) 
24  /  3  [611015  !]  15 (63 per cent) 
*  See  text. 
CF 
TABLE VI 
Titers  in  81  Poliomyelitis Patients 
Type of disease 
Paralytic 
Non-paralytic 
Uncertain 
Total .................... 
No. of  [ 
patients  .  <4  4-12  !  16-24  32-48 
47  ]  8.5  I  21.3  [  19.1  ]23.4 
T  13 6  10.0  23.3 
3~  23.3  20.0  75.0 
19.8  ] 14.8  25.9 
Patients with indicated CF titers* 
4or ~  [6 or >  32 or > 
--  70.2 
per ten  per cent  per test 
27.6  51.0 
23.3  56.7  46.7 
25.0  100.0  100.0 
25.9  66.7  51.9 
* When serial bleedings were available, the highest titer was entered. 
among  the non-paralytic patients  is  considerably greater than  among  those 
with paralysis (8.5 per cent), although the numbers are too small for statisti- 
cal significance. Since no such difference between paralytic and non-paralytic 
cases  was  found in  the  group  A  patients  from whom  virus  was  recovered~ 
that observed in the entire group may be due to the fact that a small propor- 
tion of the patients with a diagnosis of non-paralytic poliomyelitis might have 
had aseptic meningitis due to other causes. The 70 per cent incidence of titers 
of 1:16 or higher among the 47 paralytic patients is remarkably like the 69' 
per cent incidence of such titers among the 13 patients from whom non-Lansing 
strains of poliomyelitis virus were recovered. 
The  results  are  given graphically,  but  without  classification into  clinical 
types, in Fig. 1, in which it is seen that 52 per cent of the patients (42 of 81) J.  CASALS)  P.  K.  OLITSKY,  AND  A.  B.  SABIN  45 
exhibited at one time or another a positive reaction at 1: 32, or higher dilutions 
of serum, and 67 per cent (54 of 81), at 1:16, or higher. In contrast,  control 
sera,  soon to be described, showed only 2.5  per cent  (4 of 159)  positive CF 
reaction at a dilution of 1:32, or higher, and 11.3 per cent (18 of 159) at 1:i6, 
or higher. 
100 
Cumulative (hi9h~t tite~  only) 
All cotter,  =  81  90-  All  contpol~  =  159 
8C- 
70 
•  ~>  60 
% 
10  %, 
%% 
4.-6  8-12  16-24  52-48  04-96  128 
Ti%e~  and ow.r, 
•  Fzo.  1. Course of Type 2, CF antibody in poliomyelitis,  with respect to titer of reaction 
and incidence,  as compared with controls. 
Persistence of CF Antibody.--Of  the 81 patients, 58 yielded the first serum 
sample within 7 days after onset and the second after from 27 to 60 days (50 
of them after 27 to 35 days). Only 5 showed a 4-fold, or greater, titer in the 
second sample, including 2 in which this had a titer of less than 1:16. A graphic 
analysis (Fig. 2) was made with respect to the persistence of antibody, in which 
all the sera studied were grouped in 4 classes according to the time which had 
elapsed between the onset of disease and the day of serum collection. It fol- 
lows that in the graph, the same individual is not necessarily represented in 
all 4 groups. These were divided as follows:  1 to 7 days after onset, 63 sera; 
14 days, 43 sera; 28 to 57 days, in 2 subgroups: 28 to 35 days, 52 sera and 46  TYPE 2 POLIOMYELITIS COMPLEMENT-FIXING ANTIBODY 
38 to 57 days, 8 sera; and finally, 60 to 135 days in 3 subgroups: 60 to 80 days, 
3 sera; 90 days, 31 sera, and a  single sample of serum at 135 days. 
It is clear that the sera of all the groups of patients, except the last, revealed 
CF reactions  of similar pattern:  40  to  45  per  cent  of those  of the  3  groups 
yielded positive results in  1:32  dilution,  or higher,  and  55  per cent  in  1:16, 
100|  /  Co~:  "/-day  ~eeum ..... 
14  ....  o  ,,  o 
90  28  ....  x----,, 
B0"~,.  Contt~ol~:  Autumn  =  : 
I',.  k 
Ju  ;  \  ~.%  x  •  \..  ",:,, 
4-6  8-12  16-~,4  32-48  54-96  128 
Ti~e~  and ovem 
FIo. 2.  As in Fig. 1 except that poliomyelitis sera are in 4 groups with respect to time 
between onset of disease and day of serum collection; controls, in 2 groups, serum collected 
in autumn and in winter. 
or higher. In the remaining group, on the other hand, that of 60 to 135 days, 
the  titers  were  generally at  a  somewhat lower level,  although  the  difference 
could not be proved statistically significant. The titers of this last group were, 
however, far above the level of those shown by control sera. The arithmetical 
means of the four groups were: 1 to 7 days, 1:37; 14 days, 1:32; 28 to 35 days, 
1:29; and 60 to 135 days, 1:19. What has already been stated to apply to the 
thoroughly  studied  group  A  patients  in  whom  diagnoses  were  checked  by 
various available means, including virus isolation,  can therefore be said with 
equal weight for the  combined group of 81  individuals  diagnosed  on clinical 
grounds as having poliomyelitis. ft.  CASALS, P.  K.  0LITSKY,  AND  A.  B.  SABIN  47 
Control Sera.--The following observations were made on sera deriving from 
persons who gave no evidence of having had poliomyelitis and could therefore 
serve as controls. It is to be stressed here that Type 2 neutralizing antibody 
develops  with  time  and  becomes widespread  among  the  population  of the 
areas in which the present patients have dwelt,  so that by the time the age 
of 10 to  14 years is reached about  85  per cent of the population have this 
antibody (16), and in adults of low-income groups, 100 per cent (17). 
Sera were collected from 159 persons, a  single sample from each. It was considered im- 
portant to obtain specimens at seasons when the incidence of the clinical malady is highest, 
i.e. late August and September, and also when it is lowest, i.e. January to April. Moreover, 
it seemed important to have for comparison as many sera as possible in the same age groups 
as the poliomyelitis patients, namely, from 1 to 19 years. The findings are given in Table VII. 
There  were  127  control  sera  secured  during  August  to  November.  The 
number yielding positive CF reaction in dilution of 1 : 16, or higher, was from 
10 to 20 per cent of the total, regardless of the age of the patient. 
It has already been shown (18) that there is a  changing pattern in the dis- 
tribution of Type 2 neutralizing antibody in a  normal population during the 
warmer months,  that  is  to say the poliomyelitis season,  when about  20 per 
cent of the early age groups, previously free from neutralizing antibody, ac- 
quire it.  The dissemination of Type 2 virus might very well have influenced 
the results of the CF reaction. To what extent it did so was investigated by 
testing  127 normal  sera collected during the warmer months,  and 32  during 
winter and early spring, the non-epidemic period. 
The distribution of the results (Table VII) seems to indicate fewer positive 
reactions  and  lower  titers in  non-epidemic  than  in  epidemic  seasons.  The 
numbers involved are, however, too small for a statistically significant result;" 
but on inspection of Table VIII this trend is clearly observed. 
On inspection of Table IX one can see no significant difference between the 
number of positive CF reactions among the sera that had Type 2 neutralizing 
antibody and those that had none. 
Of the control sera,  80 were obtained from apparently healthy individuals 
and  79  from patients  having  rheumatic  fever, herpangina,  or diarrhea.  No 
noteworthy differences were seen  in  the  distribution  of CF  reactions in  the 
two groups. 
Thus, in the present series of control sera,  while no statistically significant 
effect on the results of CF reactions could be referred to age, season, presence 
of Type 2 neutralizing antibody or certain pathological states of the donors, 
there appears on inspection to be some relationship to season. This can be seen 
in Table X  in which all the data on control sera have been assembled. 11.3 per 
cent of the sera showed a positive CF reaction in a dilution of 1:16, or higher, 
ranging from 3.1  per cent positive, with sera collected in winter,  to  13.4 per 48  TYPE  2  POLIOMYELITIS  COMPLEMENT-FIXING  ANTIBODY 
TABLE VII 
CF  Tests  with  Control  Sera 
~'$° 
Under 1 
No.  Titer 
Bled in 
Aug.  Sept.  Oct.  Nov. 
6  <4  2 
16 
Jail. to 
Apr. 
I-4  48  <4  1  14  3 
4  1  1 
6  1 
8  6 
12  1 
16  1 
24  1 
32  1 
48  1 
11 
1 
1 
2 
1 
5-9  52  ~4  2  14  5 
4  1  2  1 
6  1  4 
8  1  2 
12  1  1 
16  2  1  1 
9 
10-14  16  <4 
8 
16 
15-19  (4 
4 
12 
16 
20 or older  29  <4 
4 
6 
8 
12 
16 
24 
32 
64 
2  2  10 
1  1 
1  2 
1 
1 
1 
1 
Tot~l.  .~!  lS9  lS  61  27  21  S2 J. CASALS, P. K. OLITSKY, AND A. B. SABIN  49 
cent in the late  summer and autumn months. The arithmetical means were 
1:2.6 for winter sera and 1:5.1 for summer and autumn. 
TABLE  VIII 
CF Tests on Normal Children under 10  Years of Age 
No. of  Sera obtained  children 
Aug., Sept., and Oct.  73 
Jan. to Apr.  32 
Children with indicated  CF titers 
--__<4  4-12  16-24  32-48 
per cent  per cent  [  per cent  per cent 
56.2  [  32.9  [  8.2  2.7 
I  71.9  I  2s.o  i  3.1 
16 or > 
peg sent 
11.0 
3.1 
TABLE IX 
Type g, CF Titers of Control  Sera in Relation to Type 2 Neutralizing Antibody 
Titer of CF antibody 
Neutralization  index  No. 
< 4  4-6  8-12  16 
50 or >  30  20  3  4  3 
10 or <  26  19  3  3  1 
TABLE X 
CF "Tests  on  Control  Sera  of All  Age  Groups 
Persons with indicated  CF titers 
Time of bleeding  No. of 
person$ 
Aug., Sept., Oct., and Nov. 
Jan. to Apr. 
Total ....................... 
127 
32 
159 
<4 
per cent 
55.9 
71.9 
59.1 
4-12 
per tens 
30.7 
25.0 
29.6 
16-24 
per cent 
10.2 
3.1 
8.8 
32-64  16 or> 
per cent  "per  cent 
3.2  13.4 
3.1 
2.5  11.3 
RECAPITULATION 
Sera from 81  patients with a  diagnosis of paralytic or non-paralytic polio- 
myelitis and from 159 controls of similar age groups, without history of polio- 
myelitis, were tested with a  high titered, Type 2  (Lansing-like) poliomyelitis, 
CF antigen derived from newborn mice inoculated with the specially adapted 
MEF1 strain. Titers of less than 1:4 (original dilution of serum) were regarded 
as negative. Among  127  controls,  bled during  the  late summer  and autumn 
months, 44 per cent gave positive reactions, 13 per cent having titers of 1:16 
or higher,  and  3  per  cent,  titers of  1:32  or higher;  among 32  controls,  bled 
during  the  winter  months,  28  per  cent  gave  positive  reactions,  only  3  per 
cent had titers of l'16 or higher, and none had titers of 1:32 or higher. Among 50  TYPE 3 POLIOMYELITIS COM~LEM2EN'T-IFIXIIN'G  ANTIBODY 
the poliomyelitis  patients,  91 per cent of 47 paralytics  gave positive  reactions 
with titers  of 1:16 or higher in 70 per cent,  and titers  of 1:32 or higher in 
51 per cent; 77 per cent of 30 non-paralytic  patients  gave positive  reactions, 
57 per cent having titers  of i:  16 or higher and 47 per cent,  titers  of 1:32 or 
higher. Among  13 patients from whom  poliomyelitis  virus was recovered, 
there was no difference  in CF antibody response between the paralytic  and 
non-paralytic cases. 
Among 58 patients, who provided acute phase and convalescent serum speci- 
mens,  there were only 5  who exhibited a  4-fold or greater increase in  titer. 
There was no evidence of either past or concurrent infection with a  Type  2 
• poliomyelitis virus in these 5 patients. The occurrence of Type 2, CF antibody 
and the magnitude of the titer bore no relationship to the presence or absence 
of neutralizing antibody for Type 2 poliomyelitis virus.  Type  1  (Brunhilde- 
like)  strains of virus were recovered from 17 of the patients, and the  CF re- 
suits  obtained  on  their  sera  conclusively established  the  fact  that  Type  1 
poliomyelitis virus  can give rise  to Type 2,  CF  antibodies  in  patients  pre- 
senting no evidence of previous or concurrent infection with Type 2 virus. 
The CF antibody was present in peak titers within 24 hours after onset of 
first symptoms in many patients and, with the 5 exceptions noted above, in 
almost all of those tested during the first 7 days. Except in 3 cases of super- 
imposed  infection with  Type  2  virus  during  convalescence,  there  were  no 
increases in titer beyond the first 2 weeks. Among 31 patients, who provided 
sera during the acute phase,  at 2 weeks, 4 weeks, and 3 months after onset, 
there were some (4 of 25) in whom the CF antibody disappeared by 3 months; 
a 4-fold or greater drop in titer occurred at S months in 9 of 18 patients who 
had titers of 1:16 or higher during the first 4 weeks. 
DISCUSSION 
The data here reported establish  the fact that  human beings who are  in- 
fected with Type 1 strains of poliomyelitis virus develop CF antibodies for a 
Type 2 poliomyelitis antigen derived from the variant MEF1 strain especially 
adapted in newborn mice. In 5  patients,  without evidence of either past  or 
concurrent infection with a Type 2 virus, a  4-fold or greater increase in titer 
of Type 2,  CF antibody occurred within  2 weeks after onset of paralytic or 
non-paralytic  poliomyelitis•  In  the  majority  of  the  other  patients  the  CF 
antibody was found in peak titers within 1 to 5 days after onset of first symp- 
toms, and the evidence that it developed during the course of the current ill- 
ness was based on the demonstration of both a strikingly higher incidence of 
positive reactions and of higher titers among the poliomyelitis patients, than 
those existing among controls with no history of clinically recognized polio- 
myelitis.  Thus,  91.5  per  cent of 47  paralytic patients  and  76.7  per  cent  of 
those diagnosed as  having non-paralytic poliomyelitis gave positive CF  reac- ~. CASALS,  P. K. OLITSKY,  AND  A. B. SABIN  51 
tions, compared to 44.1  per cent of 127  controls bled during the late summer 
and autumn months. More striking than the difference in incidence of positive 
CF reactions was the fact that 67 per cent of 81 poliomyelitis patients fielded 
titers of 1:16 or greater compared with 13 per cent among 127  summer and 
autumn controls and 3 per cent among 32 winter controls; 52 per cent of the 
81  poliomyelitis patients had titers of 1:32  or greater compared with 3 per 
cent among the  127  summer and autumn controls and none among the 32 
winter controls. 
Patients who had no evidence of previous or current infection with Type 2 
poliomyelitis virus reacted the  same as those giving evidence of past  infec- 
tion,  both  with regard  to incidence of positive reactions and high titers of 
Type 2, CF antibody. While there were 17 patients from whom Type 1 strains 
of virus were recovered,  and  the capacity of Type  1 poliomyelitis virus to 
stimulate the development of Type 2, CF antibodies in human beings is thus 
established, no information is available on the effect of Type 3 strains. The 
rapidity and persistence of the CF antibody response following primary infec- 
tion with Type 2 virus in human beings are also not known. One of 3 patients 
of the present series,  who developed inapparent Type 2 infection during con- 
valescence, exhibited a rise and fall in Type 2,  CF antibody titer comparable 
to that observed among the other patient~ infected with non-Lansing strains. 
Cynomolgus monkeys infected by the oral route with a  Type 2 poliomyelitis 
virus did not yield CF titers of greater magnitude than those found in patients 
infected with Type 1 virus (7). 
Observations  on  immunized or  convalescent monkeys have  not  thus  far 
revealed a common antigen among the 3 types of poliomyelitis virus (2-6, 13). 
The present observations on the heterotypic CF antibody response in human 
beings,  and those of Sabin  (14)  on the transitory appearance of heterotypic 
neutralizing antibodies, indicate that studies with antigens derived from the 
Type 1 and Type 3 poliomyelitis viruses will have to be carried out before such 
data can be properly applied to the diagnosis of human poliomyelitis. Prac- 
tically applicable serologic  methods are most needed in cases  of the aseptic 
meningitis syndrome, and of the "minor illness" or abortive type of disease, 
in order to establish whether they are caused by infection with poliomyelitis 
virus. Diagnosis by means of a significant rise in titer between acute phase and 
convalescent serum specimens occurred too infrequently in tests with Type 2 
antigen (only in 5  of 58  cases)  to be practically useful, although Svedmyr, 
Enders, and Holloway (6) have recently reported a significant rise in ,titer in 4 
of 7 Type 1 poliomyelitis patients tested with Type 1, CF antigen. Since only 
52 per cent of patients with non-paralytic poliomyelitis yielded Type 2,  CF 
titers of 1:16 or greater, it is clear that even a presumptive test based on the 
magnitude of the titer would fail in about 50 per cent of such patients, when 
tested only with Type 2 antigen, and a negative result would not signify ab- 52  TYPE  2  POLIOMYELITIS  COMPLEMENT-FIXING  ANTIBODY 
sence of infection with poliomyelitis virus.  Studies, similar to those here re- 
ported with Type 2  antigen, carried out with Types  1 and 3,  CF antigens 
should yield information which will indicate how CF reactions in poliomyelitis 
should be interpreted and to what extent they may be used to diagnose the 
immunologic type of virus  responsible for the  infection. It  is possible  that 
identification of the type of infecting virus might be  achieved more readily 
by tests for neutralizing antibody in tissue cultures, although here too it will be 
necessary first to determine the extent of the heterotypic response in human 
beings. 
SUMMARY 
Sera from 81 patients with a  diagnosis of paralytic or non-paralytic polio- 
myelitis, and from 159 individuals of similar age groups giving no history of 
the disease, were tested with a  high titered, complement-fixing poliomyelitis 
antigen of Type 2 (Lansing-like). The antigen consisted of brain tissue from 
newborn mice injected with the MEF1 strain of virus as previously adapted 
to these animals. The presence or absence of Type 2 neutralizing antibody in 
the sera under test was found not to affect the complement fixation. 
Positive reactions were obtained with 57 per cent of the sera deriving from 
non-paralytic patients  and in  70 per  cent from paralytics,  when the  speci- 
mens were tested at a  dilution of 1:16. The complement-fixing antibody was 
often present in highest titer as early as 24 hours after the onset of poliomye- 
litis, and in almost all instances within 7 days. In about half of the patients a 
4-fold or greater drop in titer occurred within 3 months, with little or no change 
in the others. 
The incidence of titers of 1:16 or higher with the control sera varied with the 
season of the year at which they were procured, 3 per cent of the winter samples 
proving positive and 13 per cent of the summer. 
The tests of sera from the group of patients from whom poliomyelitis virus 
was recovered, disclosed no significant differences between those having the 
paralytic and those having the non-paralytic disease. 
Type 1 (Brunhilde-like) strains of virus were recovered from many of the 
patients yielding positive tests,  although they presented no evidence of pre- 
vious or concurrent infection with Type 2 virus. This finding shows that Type 
1 virus can give rise in patients to Type 2 complement-fixing antibody. 
The  application  of  these  data  to  the  serologic  diagnosis of poliomyelitis 
infection in man will of necessity be limited until information is obtained on 
the  development, persistence,  and  significance of  complement-fixation reac- 
tions with antigens deriving from Type 1 and Type 3 poliomyelitis strains. 
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